Acesso livre
Acesso livre

Covid-19

Revisão | Covid-19: virologia, variantes e vacinas.

19 Abr, 2022 | 12:48h

Covid-19: virology, variants, and vaccines – BMJ Medicine

 

Comentário no Twitter

 

Análise baseada em evidências | Fatores que influenciam a efetividade estimada das vacinas contra COVID-19 em estudos não randomizados.

19 Abr, 2022 | 12:47h

Factors influencing estimated effectiveness of COVID-19 vaccines in non-randomised studies – BMJ Evidence-Based Medicine

 

Comentário no Twitter

 

Estudo de coorte | Mudanças na incidência de oclusões vasculares da retina após diagnóstico de COVID-19.

19 Abr, 2022 | 12:42h

Changes in the Incidence of Retinal Vascular Occlusions After COVID-19 Diagnosis – JAMA Ophthalmology

Comentários:

COVID-19 Diagnosis and Incidence of Retinal Thromboembolism – JAMA Ophthalmology

Threatening Eye Condition Rare After COVID Infection – HealthDay

M-A | Miopericardite após vacinação contra COVID-19 e vacinação não relacionada a COVID-19.

19 Abr, 2022 | 12:41h

Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis – The Lancet Respiratory Medicine

Comentários:

Myopericarditis following COVID-19 vaccination is rare, finds international study – The Lancet

Myopericarditis after COVID-19 vaccination: unexpected but not unprecedented – The Lancet Respiratory Medicine

Study explores myopericarditis incidence and COVID-19 vaccination – News Medical

 

Comentário no Twitter

 

Análise observacional em Israel mostrou que a 4ª dose da vacina da Pfizer pode reduzir o risco de curto prazo dos desfechos adversos relacionados a Covid-19.

18 Abr, 2022 | 15:31h

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting – New England Journal of Medicine

Editorial: Covid-19 Boosters — Where from Here?

Conteúdos relacionados:

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines.

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Comentário no Twitter

 

Covid-19: qual é a evidência para o uso do antiviral molnupiravir?

18 Abr, 2022 | 15:30h

Covid-19: What is the evidence for the antiviral molnupiravir? – The BMJ

Estudo mostrou baixas taxas de COVID-19 grave em crianças internadas com infecção por SARS-CoV-2 confirmada.

18 Abr, 2022 | 15:29h

Very low rates of severe COVID-19 in children hospitalised with confirmed SARS-CoV-2 infection in London, England – Journal of Infection

Comentário: Severe COVID-19 extremely rare among children – News Medical

Conteúdos relacionados:

[Preprint] Risk of Hospitalization, severe disease, and mortality due to COVID-19 in children with SARS-CoV-2 infection in Germany – “overall hospitalization rate associated with SARS-CoV-2 infection was 35.9 per 10,000 children, ICU admission rate was 1.7 per 10,000 and case fatality was 0.09 per 10,000”.

Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year – “In total, 99.995% of children and young people with a positive SARS-CoV-2 test survived”.

Editorial: COVID-19 vaccines for children – “Although it is true that most children experience asymptomatic or mild disease, some will get quite sick, and a small number will die. It’s why children are vaccinated against influenza, meningitis, chickenpox, and hepatitis”.

COVID-19 disease severity in children infected with the Omicron variant.

Risk factors for PICU admission and death among children and young people hospitalized with COVID-19 and PIMS-TS in England during the first pandemic year.

Study identifies risk factors for severe CoviD-19 in children.

A nationwide cohort study in Denmark showed Long Covid in children is rare and mainly of short duration.

International study identifies predictors of severe outcomes in children with COVID-19.

Perspectiva | O conceito clássico de imunidade de rebanho pode não se aplicar à COVID-19.

14 Abr, 2022 | 17:46h

The Concept of Classical Herd Immunity May Not Apply to COVID-19 – The Journal of Infectious Diseases

Comunicado de imprensa: NIH experts discuss controlling COVID-19 in commentary on herd immunity – NIH News Releases

 

Comentário no Twitter

 

Estudo de coorte | Risco de eventos adversos após Covid-19 em crianças e adolescentes dinamarqueses e efetividade da vacina da Pfizer em adolescentes.

14 Abr, 2022 | 17:04h

Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study – The BMJ

Diretriz científica AHA | Infecção por SARS-CoV-2 e manifestações cardiovasculares associadas em crianças e jovens adultos.

14 Abr, 2022 | 16:59h

SARS-CoV-2 Infection and Associated Cardiovascular Manifestations and Complications in Children and Young Adults: A Scientific Statement From the American Heart Association – Circulation

Comunicado de imprensa: Heart issues after COVID-19 uncommon in children and young adults, more research needed – American Heart Association

Comentário: COVID-19 CV Complications in Children Are Rare, Treatable: AHA Statement – TCTMD

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.